Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution
NCT ID: NCT03421015
Last Updated: 2019-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
84 participants
OBSERVATIONAL
2017-05-01
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Prostate Cancer Genes
NCT00342784
Understanding of Genetics by Men at Risk for Prostate Cancer
NCT04550845
Epidemiologic and Genetic Study on Familial Prostate Cancer
NCT01221168
Prostate Cancer Screening in Men With Germline BRCA2 Mutations
NCT02154672
Men at High Genetic Risk for Prostate Cancer
NCT03805919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case group
patients with biochemical recurrence and positive imaging (case group)
No interventions assigned to this group
Control Group
patients without biochemical recurrence (control group)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follow up \> 6 years
* Negative pre surgical extension assessment
* Prognostic Grade Groups (OGG) III-IV-V
* Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL
* Metastasis positive imaging
Exclusion Criteria
* Follow up \< 6 years
* Prognostic Grade Groups (PGG) I-II
* Biochemical recurrence with metastasis negative imaging
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Weill Medical College of Cornell University
OTHER
New York Presbyterian Hospital
OTHER
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnauld Villers, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Claude Huriez, CHRU
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A01870-53
Identifier Type: OTHER
Identifier Source: secondary_id
2017_12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.